TR200200802T2 - Aşı - Google Patents

Aşı

Info

Publication number
TR200200802T2
TR200200802T2 TR2002/00802T TR200200802T TR200200802T2 TR 200200802 T2 TR200200802 T2 TR 200200802T2 TR 2002/00802 T TR2002/00802 T TR 2002/00802T TR 200200802 T TR200200802 T TR 200200802T TR 200200802 T2 TR200200802 T2 TR 200200802T2
Authority
TR
Turkey
Prior art keywords
development
protein
oligo
polynucleotide
infections
Prior art date
Application number
TR2002/00802T
Other languages
English (en)
Inventor
Antonsson Per
Kristensson Karin
Wallen-�Hman Marie
Dillner Joakim
Lando Peter
Original Assignee
Active Biotech Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Active Biotech Ab filed Critical Active Biotech Ab
Publication of TR200200802T2 publication Critical patent/TR200200802T2/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/025—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Plant Pathology (AREA)
  • Gynecology & Obstetrics (AREA)

Abstract

Bulus, insan papilloma virüsünün majör kapsid proteininin L1(HPV-L1proteini) hücrelere verilebilmesi için kullanilacak ve nötralize edici antikorlarin üretimine sebep olan spesifik tip epitoplari ayirmak için özellikle modifiye bir tasiyiciyla ilgilidir.Bulus ayrica adi geçen tasiyicinin oligo-veya polinükleotid kodlarini,adi geçen tasiyicidan veya adi geçen oligo-veya polinükleotidden olusan asilari, ve ayrica bu tasiyicinin veya oligo-veya polinükleotidin insan papilloma virüs enfeksiyonlarina karsi veya bu gibi enfeksiyonlarin sonuçlarinin gelismesine karsi,veya belli kanserlerin gelismesine karsi hazirlanacak asilarda kullanilmasini da içerir.
TR2002/00802T 1999-09-30 2000-09-19 Aşı TR200200802T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9903534A SE514982C2 (sv) 1999-09-30 1999-09-30 Bärare innehållande ett huvudkapsidprotein L1 från humant papillomavirus samt dess användning

Publications (1)

Publication Number Publication Date
TR200200802T2 true TR200200802T2 (tr) 2002-09-23

Family

ID=20417209

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2002/00802T TR200200802T2 (tr) 1999-09-30 2000-09-19 Aşı

Country Status (25)

Country Link
EP (1) EP1222200B1 (tr)
JP (1) JP2003510064A (tr)
KR (1) KR20020047195A (tr)
CN (1) CN1373771A (tr)
AT (1) ATE313559T1 (tr)
AU (1) AU771481B2 (tr)
BR (1) BR0014666A (tr)
CA (1) CA2384723A1 (tr)
CZ (1) CZ20021023A3 (tr)
DE (1) DE60025016D1 (tr)
EE (1) EE200200157A (tr)
HR (1) HRP20020092A2 (tr)
HU (1) HUP0202770A3 (tr)
IL (1) IL148741A0 (tr)
MX (1) MXPA02003328A (tr)
NO (1) NO20020615L (tr)
NZ (1) NZ516725A (tr)
PL (1) PL355012A1 (tr)
RU (1) RU2002111554A (tr)
SE (1) SE514982C2 (tr)
SK (1) SK4222002A3 (tr)
TR (1) TR200200802T2 (tr)
WO (1) WO2001023422A1 (tr)
YU (1) YU22202A (tr)
ZA (1) ZA200200886B (tr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY139500A (en) * 2003-11-12 2009-10-30 Merck Sharp & Dohme Optimized expression of hpv 58 l1 in yeast
BRPI0509079B8 (pt) * 2004-03-24 2021-07-06 Merck & Co Inc molécula de ácido nucléico, vetor, célula hospedeira, partículas tipo vírus, método para produzir vlps, vacina, composições farmacêuticas, e, métodos para evitar infecção por hpv e para induzir uma resposta imune em um animal
DE102004036913A1 (de) * 2004-07-16 2006-02-09 Responsif Gmbh Verwendung von Pentameren zur Herstellung eines Medikaments
CN1796403B (zh) * 2004-12-22 2010-04-28 三峡大学 用于多型人乳头瘤病毒感染防治的多肽和疫苗
CN100392084C (zh) * 2006-03-13 2008-06-04 曾毅 含密码子优化型hpv16l1基因的重组腺病毒
CN101914139B (zh) * 2010-07-16 2012-11-21 四川大学 人类乳头瘤病毒(hpv)衣壳蛋白l1多肽及其制备与应用
MY202196A (en) 2017-06-23 2024-04-16 Verimmune Inc Chimeric virus-like particles and uses thereof as antigen-specific redirectors of immune responses
WO2020139978A1 (en) 2018-12-27 2020-07-02 Verimmune Llc Conjugated virus-like particles and uses thereof as anti-tumor immune redirectors
EP3920967A4 (en) * 2019-02-08 2023-01-18 Rensselaer Polytechnic Institute CONTRACEPTIVE VACCINE BASED ON SPER-ASSOCIATED PROTEIN CATSPER
AU2021364548A1 (en) 2020-10-19 2023-06-08 Verimmune Inc. Virus-inspired compositions and methods of redirecting preexisting immune responses using the same for treatment of cancer

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4270196A (en) * 1994-10-07 1996-05-02 Lutz Gissmann Papilloma virus-like particles, fusion proteins and process for producing the same
FR2768749A1 (fr) * 1997-09-22 1999-03-26 Inst Nat Sante Rech Med Virus artificiels derives de papillomavirus, et leurs utilisations, notamment en therapie genique
DE19812941A1 (de) * 1998-03-24 1999-10-07 Medigene Ag Arzneimittel zur Vermeidung oder Behandlung von Papillomavirusspezifischem Tumor

Also Published As

Publication number Publication date
ATE313559T1 (de) 2006-01-15
NZ516725A (en) 2003-03-28
NO20020615L (no) 2002-05-29
SE9903534D0 (sv) 1999-09-30
YU22202A (sh) 2005-06-10
CA2384723A1 (en) 2001-04-05
KR20020047195A (ko) 2002-06-21
DE60025016D1 (de) 2006-01-26
JP2003510064A (ja) 2003-03-18
EE200200157A (et) 2003-04-15
ZA200200886B (en) 2003-03-26
HUP0202770A2 (hu) 2002-12-28
HUP0202770A3 (en) 2004-07-28
CZ20021023A3 (cs) 2002-07-17
WO2001023422A1 (en) 2001-04-05
RU2002111554A (ru) 2004-03-27
MXPA02003328A (es) 2004-09-10
CN1373771A (zh) 2002-10-09
HRP20020092A2 (en) 2003-06-30
EP1222200B1 (en) 2005-12-21
IL148741A0 (en) 2002-09-12
AU771481B2 (en) 2004-03-25
PL355012A1 (en) 2004-03-22
BR0014666A (pt) 2002-06-18
EP1222200A1 (en) 2002-07-17
NO20020615D0 (no) 2002-02-08
SK4222002A3 (en) 2002-10-08
SE9903534L (sv) 2001-03-31
AU7695100A (en) 2001-04-30
SE514982C2 (sv) 2001-05-28

Similar Documents

Publication Publication Date Title
CY1118443T1 (el) Anti-tnf αντισωματα, συνθεσεις, μεθοδοι και χρησεις
CY1107628T1 (el) Ανθρωπινα ctla-4 αντισωματα και χρησεις αυτων
CY1118492T1 (el) Φαρμακοτεχνικες μορφες εμβολιου norovirus
NO20022531L (no) Vaksine for forebyggelse og behandling av Alzheimer- og amyloidrelaterte sykdommer
NO20065366L (no) Antistoffer og molekyler som er avledet fra disse som binder til STEAP-1-proteiner
EA202090757A1 (ru) T-КЛЕТОЧНЫЕ РЕЦЕПТОРЫ, РАСПОЗНАЮЩИЕ МУТАНТНЫЙ p53
CY1117746T1 (el) Αντιγονα αιμοφιλου της γριπης και αντιστοιχα θραυσματα dna
UA93855C2 (ru) Вакцина, способствует росту, базирующейся ha нейтрализующем эпитопе
UA85536C2 (en) Viral antigens
MXPA02005639A (es) Induccion de respuestas celulares iinmunologicas al virus de papiloma humano y utilizacion de composiciones de peptidos y acidos nucleico.
TR200103012T2 (tr) Yeni kompozisyonlar
TR200200472T2 (tr) Anti-Erb B2 antikorları ile tedavi için dozajlar
ZA200603731B (en) Plasmid system for multiple expression
MY125202A (en) Vaccine
BR9809656A (pt) Composição imunopotencializante
SI1644484T1 (sl) Avtologne samo-toleranco inducirajoče celice monocitnega izvora in njihova uporaba v farmacevtskihpripravah
DE68927348D1 (de) Künstlicher impfstoff gegen aids-virus
ATE556717T1 (de) Neutralisierung monoklonaler antikörper gegen mit schwerem akutem respirationssyndrom assoziiertem coronavirus
ATE551069T1 (de) Mucin-fusionspolypeptid-vakzine, zusammensetzungen und ihre verwendung
TR200102034T2 (tr) Anti kanser aşılaması için antikorların kullanılması
TR200103339T2 (tr) Geliştirilmiş çözülürlük özelliklerine sahip yeni LHRH-antagonistleri.
AU2002309259A1 (en) Improved polysaccharide and glycoconjugate vaccines_____________
DK1290160T3 (da) Humane Pellino-polypeptider
NO20020615L (no) Vaksine
ATE283066T1 (de) Impfstoff enthaltend zytokin-induzierte heat shock proteine (hsp)